RxSight (RXST) Insider Raymond Cohen Buys 30,864 Shares

Insider Buying and Selling at RxSight, Inc.

Raymond Cohen added 30,864 shares of RxSight, Inc. (RXST) to his holdings on June 17, 2026. This purchase was not an isolated event; it was part of a coordinated series of buys by the company's board of directors. On the same day, six other insiders each purchased exactly 37,037 shares. This group included Julie Andrews, Tamara Fountain, Corley Jesse Anderson, Shweta Maniar, Link William Phd, and Robert Palmisano. None of these transactions were made under a Rule 10b5-1 trading plan, which is a pre-set schedule often used by executives to sell shares.

This cluster of buying suggests a shared sentiment among those closest to the company's leadership. While earlier reports from June 17 detailed individual purchases by directors like Julie Andrews and Tamara Fountain, the addition of Cohen to the list rounds out a significant day of activity for the Aliso Viejo-based medical device maker.

RxSight Stock Performance

On Friday, shares of RxSight were trading at $4.73. The stock has faced a difficult stretch over the past year, currently sitting much closer to its 52-week low of $4.48 than its high of $13.22. The current price is also well under its 50-day moving average of $6.09, showing a downward trend in the short term. With a market value of roughly $213.8 million, the company is navigating a volatile period for medical technology stocks.

Financial Health and Earnings Outlook

RxSight reported revenue of $127.58 million in its most recent period, with a very slight growth rate of 0.3%. The company is currently not profitable, reporting a net margin of negative 36.8% and a return on equity of negative 17.3%. Because it is losing money, the company has no meaningful P/E ratio. Investors are looking ahead to the next financial update, with the company scheduled to report its next round of earnings on November 4, 2026.

Analysts Set New Price Targets

Wall Street remains mostly neutral on RxSight. On September 22, 2026, Jefferies maintained a Hold rating but cut its price target to $5.75 from $6.50. B of A Securities also lowered its target that same day to $5.50, keeping an Underperform rating. Earlier in the summer, Stifel maintained a Hold rating with a $7.00 target on August 10, while UBS kept a Neutral rating with a $6.30 target on August 6. Needham stands out as the most optimistic, reiterating a Buy rating with an $11.00 price target on July 7. Overall, eight analysts provide a consensus Hold rating with an average target price of $7.79.

Eye Surgery Technology

RxSight is a medical technology company that specializes in cataract surgery. It makes a special type of intraocular lens that can be adjusted with ultraviolet light after it has been implanted in a patient's eye. This allows doctors to fine-tune a patient's vision after the surgery is over, rather than relying on a one-size-fits-all lens. The company’s primary products are the Light Adjustable Lens and the Light Delivery Device used to program the vision correction.

What to Watch at RxSight, Inc.

Investors should keep an eye on whether this wave of insider buying continues as the stock sits near multi-month lows. The upcoming earnings report on November 4 will be a key moment to see if the company can improve its margins or accelerate revenue growth. While insider buying is often viewed as a positive sign, it is just one piece of the puzzle, and these transactions occurred in June, meaning they reflect the board's outlook from several months ago.